(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 October 2013 (10.10.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/150150 A1

(51) **International Patent Classification**:
A61K 31/4725 (2006.01) *A61P 25/28* (2006.01)

(21) **International Application Number**:
PCT/EP2013/057241

(22) **International Filing Date**:
5 April 2013 (05.04.2013)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
12305415.7 6 April 2012 (06.04.2012) EP
61/792,635 15 March 2013 (15.03.2013) US

(71) **Applicant**: **SANOFI** [FR/FR]; 54 rue La Boétie, F-75008 Paris (FR).

(72) **Inventors**: **BARNEOUD, Pascal**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). **BLANCHARD-BREGEON, Véronique**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). **DELAYGOYET, Philippe**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). **MARY, Véronique**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). **MENAGER, Jean**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). **LOPEZ GRANCHA, Mathilde**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). **ROONEY, Thomas**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR). **SCHUSSLER, Nathalie**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR).

(74) **Agent**: **TINEL, Marie Line**; c/o Sanofi, Patent Department, 54 rue La Boétie, F-75008 Paris (FR).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2013/150150 A1

(54) **Title**: AN H3 RECEPTOR ANTAGONIST FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE

(57) **Abstract**: This disclosure relates to methods of using 2-(cyclohexylmethyl)-N-{2-[(2S)-1- methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of Alzheimer's disease, other tauopathies and related neurodegenerative diseases.